BiotechTV - News - TopPodcast.com

Latest Episodes:

Soufflé Therapeutics exited stealth today with the goal of developing nucleic acid therapies, like siRNAs and ASOs, delivered to any cell in the body by targeting internalizing receptors Oct 07, 2025

Show notes

CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and design ligands that carry payloads to them such as siRNAs and ASOs. The company plans to be in the clinic next year and is starting out with muscle conditions.

Brian Alexander, former CEO of Foundation Medicine, describes how Valo Health is using its AI expertise to partner with companies and foundations on discovery and development projects Oct 03, 2025

Show notes

The company recently received a grant from the Michael J. Fox Foundation to work on Parkinson's, and has existing partnerships with companies such as Novo and Charles River.

Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB Oct 01, 2025

Show notes

Chief Executive Officer Jack O'Meara, who previously founded Ochre Bio in the RNA space, describes the potential benefits of using brain shuttles and why the time is right for this approach. Plus, the company's business model and what to expect next.

Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company Sep 29, 2025

Show notes

CEO Jay Luly and CMO Scott Rottinghaus describe today's data, which was focused on high risk adults. They explain how safety and efficacy were measured, and what the learnings were from a handful of endpoints. Plus, Enanta's earlier stage I&I programs targeting KIT and STAT6.

Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare Sep 26, 2025

Show notes

He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how the practice of medicine might be changed in the process.

Eko Health's Co-Founder & CEO shows BiotechTV the company's digital stethoscope and explains how having both an electric and sound component can help physicians catch heart disease (and more) earlier Sep 19, 2025

Show notes

Connor Landgraf shows us the product and describes recent data the company compiled in the UK showing the benefits of using this digital and AI enhanced device over a traditional stethoscope.

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more. Sep 18, 2025

Show notes

He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.

Xspray Pharma makes protein kinase inhibitors that are amorphous, and therefore more soluble than current products. Dasynoc, its version of dasatinib (Sprycel), is in front of FDA with an Oct 7 PDUFA Sep 17, 2025

Show notes

CEO Per Andersson walks us through the benefits of designing kinase inhibitors this way, which should not be affected by the pH of the stomach. He shows us the unique manufacturing equipment, and walks us through a pipeline that includes dasatinib, nilotinib, axitinib, and cabozantinib.

Pareto Securities Healthcare Conference: Egetis Therapeutics has a therapy for a rare disease called MCT8 deficiency that is approved by the EMA and has breakthrough therapy designation in the U.S. Sep 16, 2025

Show notes

CEO Nicklas Westerholm walks us through the condition, which is an X-chromosome linked rare disease that affects men, and he describes how the launch is going in Europe, and plans for an FDA meeting.

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to user in the next generation of acid reflux medicines with, linaprazan glurate, a potassium-competitive acid blocker (P-CAB) Sep 16, 2025

Show notes

CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected